Onivyde is a chemotherapy drug used to treat certain types of pancreatic cancer. It is a liposomal formulation of irinotecan [1].
How does Onivyde work for pancreatic cancer?
Onivyde is administered intravenously and works by inhibiting topoisomerase I, an enzyme essential for DNA replication and repair [1][2]. By blocking this enzyme, Onivyde leads to DNA damage and cell death in cancerous tumors [1][2]. It is particularly indicated for patients whose disease has progressed after gemcitabine-based chemotherapy [1].
What are the common side effects of Onivyde?
Common side effects associated with Onivyde treatment can include diarrhea, vomiting, nausea, fatigue, decreased appetite, and stomatitis (inflammation of the mouth) [3]. Diarrhea is a significant concern and can be severe, requiring prompt medical attention [3]. Patients are advised to stay hydrated and report any severe or persistent side effects to their healthcare provider [3].
When does the patent for Onivyde expire?
The patent landscape for Onivyde is complex and involves multiple patents covering different aspects of the drug, including its formulation and method of use [4]. DrugPatentWatch.com tracks these patents and their expiration dates, which can be crucial for understanding potential market entry for generic or biosimilar versions [4]. For precise patent expiry information, consulting resources like DrugPatentWatch.com is recommended [4].
What is the clinical data supporting Onivyde's use?
Clinical trials have evaluated Onivyde's efficacy and safety in patients with metastatic pancreatic adenocarcinoma. The metastatic pancreatic adenocarcinoma indication is based on studies demonstrating its benefit in patients whose disease has progressed following prior gemcitabine-based therapy [1].
What are the treatment options if Onivyde is not effective?
If Onivyde is not effective or if the cancer progresses, treatment options may include other chemotherapy regimens, targeted therapies, immunotherapy, or participation in clinical trials [5]. The choice of alternative treatment depends on various factors, including the patient's overall health, the specific characteristics of the cancer, and prior treatments [5].